A detailed history of Ameritas Investment Partners, Inc. transactions in Insmed Inc stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 13,786 shares of INSM stock, worth $923,662. This represents 0.01% of its overall portfolio holdings.

Number of Shares
13,786
Previous 14,309 3.66%
Holding current value
$923,662
Previous $443,000 15.58%
% of portfolio
0.01%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$25.72 - $29.94 $13,451 - $15,658
-523 Reduced 3.66%
13,786 $374,000
Q4 2023

Feb 14, 2024

BUY
$23.42 - $31.74 $28,385 - $38,468
1,212 Added 9.25%
14,309 $443,000
Q3 2023

Nov 13, 2023

BUY
$19.86 - $26.93 $45,280 - $61,400
2,280 Added 21.08%
13,097 $330,000
Q4 2022

Feb 13, 2023

BUY
$16.98 - $23.15 $27,134 - $36,993
1,598 Added 17.33%
10,817 $216,000
Q4 2021

Feb 11, 2022

BUY
$25.89 - $33.45 $10,485 - $13,547
405 Added 4.59%
9,219 $251,000
Q3 2021

Nov 15, 2021

BUY
$22.46 - $29.47 $13,004 - $17,063
579 Added 7.03%
8,814 $243,000
Q1 2021

May 14, 2021

SELL
$32.28 - $44.3 $12,653 - $17,365
-392 Reduced 4.54%
8,235 $280,000
Q3 2020

Nov 13, 2020

SELL
$26.0 - $34.5 $8,242 - $10,936
-317 Reduced 3.54%
8,627 $277,000
Q2 2020

Aug 05, 2020

BUY
$14.11 - $29.42 $16,353 - $34,097
1,159 Added 14.89%
8,944 $246,000
Q4 2019

Feb 13, 2020

BUY
$16.12 - $24.98 $6,125 - $9,492
380 Added 5.13%
7,785 $186,000
Q3 2019

Nov 14, 2019

BUY
$15.49 - $25.78 $16,388 - $27,275
1,058 Added 16.67%
7,405 $131,000
Q4 2017

Feb 14, 2018

BUY
$26.43 - $31.78 $26,430 - $31,780
1,000 Added 18.7%
6,347 $198,000
Q2 2017

Aug 15, 2017

BUY
N/A
5,347
5,347 $92,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.08B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.